UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~December 2012

Commission File Number: 001-34564

China Nuokang Bio-Pharmaceutical Inc.

No. 18-1 East Nanping Road

Hunnan National New & High-tech Development Zone

Shenyang, Liaoning Province

People’s Republic of China 110171

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

China Nuokang Bio-Pharmaceutical Inc. By: /s/ Baizhong Xue Name: Baizhong Xue Title: Chairman and Chief Executive Officer

~~Name~~Date: ~~Baizhong~~December ~~Xue~~17, ~~Title:~~2012 ~~Chairman and Chief Executive Officer~~

Date: November 27, 2012

Exhibit Index


Exhibit No.		Description

Exhibit 99.1		Press Release

Exhibit 99.1

China Nuokang Bio-Pharmaceutical Inc. ~~Reports~~Announces

~~Third~~Extraordinary ~~Quarter 2012~~General ~~Financial~~Meeting ~~Results~~of Shareholders

~~3Q12~~BEIJING, ~~Revenue~~Dec. ~~was~~14, ~~RMB75~~2012 (GLOBE NEWSWIRE) — China Nuokang Bio-Pharmaceutical Inc.4 ~~Million~~(Nasdaq: NKBP) (~~$12~~“Nuokang” or the “Company”), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held at 9:30 a.0m. ~~Million~~(Beijing time) on January 15, 2013, at 26th Floor, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the “Merger Agreement”) dated September 27, 2012, among the Company, Kingbird Investment Inc. (“Parent”) and Kingbird Mergerco. Inc. (“Merger Sub”), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached as Exhibit A to the Merger Agreement (the “Plan of Merger”) and the transactions contemplated thereby (including the merger).

~~3Q12~~Pursuant ~~Net~~to ~~Income~~the ~~was~~Merger ~~RMB2~~Agreement and the Plan of Merger, Merger Sub will merge with and into the Company, with the Company continuing as the surviving company.5 ~~Million~~If completed, the merger will result in the Company becoming a privately-held company and its American depositary shares ($0“ADSs”) will no longer be listed on The NASDAQ Global Market and the American depositary shares program for the ADSs will terminate.4 ~~Million~~The Company’s board of directors unanimously recommends that the shareholders and ADS holders vote FOR, among other things, the proposal to authorize and approve the Merger Agreement, the Plan of Merger and the transactions contemplated thereby (including the merger).

~~3Q12~~Shareholders ~~Non-GAAP~~of ~~Adjusted~~record ~~Net~~at ~~Income~~the ~~was~~close ~~RMB11~~of business in the Cayman Islands on January 5, 2013 will be entitled to vote at the EGM and any adjournment thereof.6 ~~Million~~The record date for ADS holders entitled to instruct JPMorgan Chase Bank, N.A., the ADS depositary, to vote the shares represented by the ADSs is the close of business in New York City on December 17, 2012. Additional information regarding the EGM and the Merger Agreement can be found in the Transaction Statement on Schedule 13E-3, and the proxy statement attached as Exhibit ($a)(1) thereto, filed with the U.8S ~~Million~~Securities and Exchange Commission (“SEC”), which can be obtained from the SEC’s website (http://www.sec.gov). INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

~~Live~~This ~~conference~~announcement ~~call~~is toneither bea ~~held~~solicitation ~~Monday,~~of ~~November 26~~a proxy, ~~2012~~an atoffer ~~8:00~~to ampurchase ETnor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that have been or will be made with the SEC.

Beijing, China, November 25, 2012 – China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) (“Nuokang” or the “Company”), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced its unaudited financial results for the third quarter of 2012.

Mr. Baizhong Xue, the Company’s Chairman and Chief Executive Officer, stated, “We are pleased to report a solid third quarter that has demonstrated steady sales performance and continuing progress with non-GAAP profitability. Revenue of RMB69.9 million from Baquting, our flagship product, was largely in line with our target. Sales volume of Baquting has consistently increased during the first three quarters of this year. We are encouraged by overall longitudinal improvements that the Company has made so far for 2012.”

Chairman Xue continued, “We recently celebrated the 15th anniversary of Nuokang. During the past decade and a half, our management and staff have striven to make Nuokang one of China’s leading biopharmaceutical companies. We are extremely grateful for the support of our investors and very proud of the market-leading position we have achieved in the hemocoagulase sector. We also see tremendous potential with our increasingly diversified product portfolio. We remain committed to investing in R&D to support innovation of novel products as well as improvements to our proven product lines.”

Third Quarter 2012 Financial Highlights

• Revenue was RMB75.4 million ($12.0 million)1, compared to RMB87.2 million in the prior year period;

• Baquting revenue was RMB69.9 million ($11.1 million), compared to RMB83.9 million in the prior year period;

• Gross profit was RMB66.4 million ($10.6 million), compared to RMB75.5 million in the prior year period;

• Gross margin was 88.0%, compared to 86.6% in the prior year period;

• Operating income was RMB5.1 million ($0.8 million), compared to RMB16.5 million in the prior year period;

• Net income was RMB2.5 million ($0.4 million), or RMB0.13 ($0.02) per diluted ADS2, compared to RMB7.6 million, or RMB0.39 per diluted ADS, in the prior year period; and

• Non-GAAP adjusted net income was RMB11.6 million ($1.8 million), compared to RMB13.1 million in the prior year period.

Third Quarter 2012 Financial Performance

Revenue for the third quarter of 2012 was RMB75.4 million ($12.0 million), compared to RMB87.2 million in the third quarter of 2011. Revenue from Baquting decreased to RMB69.9 million ($11.1 million) in the third quarter of 2012 from RMB83.9 million in the third quarter of 2011 but was in line sequentially with RMB68.9 million in the second quarter of 2012. In terms of volume, Baquting sales saw both annual and sequential increases during the reporting period. The year-on-year decrease in Baquting revenue was primarily attributable to changes in the Company’s sales channel mix during the period. Baquting revenue as a percentage of total revenue was 92.7% in the third quarter of 2012, compared to 96.1% in the third quarter of 2011. Revenue from other products was RMB5.5 million ($0.9 million) in the third quarter of 2012, compared to RMB3.3 million in the third quarter of 2011, mainly attributable to increased Kaitong sales.

1 This announcement contains translations of certain Renminbi amounts into US dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the quarter ended September 30, 2012, were made at the noon buying rate of RMB6.2848 to USD1.00 on September 28, 2012 in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Nuokang Bio-Pharmaceutical Inc. makes no representation that the Renminbi or US dollar amounts referred to in this press release could have been or could be converted into US dollars or Renminbi, at any particular rate or at all.

2 The Company’s American Depositary Shares, which are traded on the NASDAQ, each of which represents eight ordinary shares of the Company.

Gross profit for the third quarter of 2012 was RMB66.4 million ($10.6 million), compared to RMB75.5 million for the third quarter of 2011. Gross margin for the third quarter of 2012 was 88.0%, an increase from 86.6% in the third quarter of 2011.

Operating income for the third quarter of 2012 was RMB5.1 million ($0.8 million), compared to RMB16.5 million for the third quarter of 2011. The year-over-year decrease was primarily attributable to expenses relating to the Company’s going-private transaction.

Research and development expenses for the third quarter of 2012 were RMB4.1 million ($0.7 million), compared to RMB4.6 million for the third quarter of 2011. Research and development expenses as a percentage of revenue was 5.5% for the third quarter of 2012, which was largely in line with 5.3% for the third quarter of 2011 and within the Company’s expected range.

Selling, marketing and distribution expenses for the third quarter of 2012 were RMB37.6 million ($6.0 million), compared to RMB41.6 million for the third quarter of 2011. Selling, marketing and distribution expenses as a percentage of revenue for the third quarter of 2012 was 49.9%, which was largely in line with 47.7% in the third quarter of 2011. Selling, marketing and distribution expenses for the third quarter of 2012 primarily consisted of the Company’s investment in sales and marketing for Baquting as well as the Company’s continued investment in the commercialization of Kaitong and ALA.

General and administrative expenses for the third quarter of 2012 were RMB19.5 million ($3.1 million), compared to RMB12.8 million for the third quarter of 2011. The increase in general and administrative expenses was primarily attributable to the Company’s privatization expenses amounting to RMB7.6 million ($1.2 million).

Provision for income taxes for the third quarter of 2012 was RMB3.6 million ($0.6 million), compared to RMB7.1 million for the third quarter of 2011. The Company’s effective tax rate was 58.9% during the third quarter of 2012, compared to 48.3% during the third quarter of 2011, primarily as a result of more non-deductible expenses such as privatization expenses incurred in this period.

Net income for the third quarter of 2012 was RMB2.5 million ($0.4 million), or RMB0.13 ($0.02) per diluted ADS, compared to RMB7.6 million, or RMB0.39 per diluted ADS, for the third quarter of 2011.

Non-GAAP adjusted net income for the third quarter of 2012, excluding foreign exchange losses, ESOP related charges, ASC 740 adjustment and privatization expenses, was RMB11.6 million ($1.8 million), compared to RMB13.1 million for the third quarter of 2011.

For the third quarter of 2012, the Company had approximately 154.4 million weighted average diluted ordinary shares outstanding, or 19.3 million weighted average diluted ADSs.

As of September 30, 2012, the Company had cash and cash equivalents and other short-term investments of RMB185.9 million ($29.8 million), compared to RMB179.4 million as of December 31, 2011.

Nine Months Ended September 30, 2012 Financial Performance

Revenue decreased 9.8% to RMB208.6 million ($33.2 million) for the nine months ended September 30, 2012 from RMB231.3 million for the nine months ended September 30, 2011. During this same time period, gross profit decreased 9.8% to RMB182.7 million ($29.1 million) from RMB202.7 million and operating income decreased by 65.7% to RMB19.1 million ($3.0 million) from RMB55.5 million.

Net income decreased 58.0% to RMB13.7 million ($2.2 million), or RMB0.09 ($0.01) per diluted ADS from RMB32.7 million, or RMB0.21 per diluted ADS, for the nine months ended September 30, 2011. Weighted average number of diluted ordinary shares outstanding was approximately 154.2 million for the nine months of 2012, or 19.3 million ADSs.

Non-GAAP Measures

Adjusted net income is presented to better illustrate the Company’s ongoing and core operational results. Adjusted net income is defined as net income excluding foreign exchange losses, ESOP related charges, ASC 740 adjustment and the Company’s privatization expenses. Adjusted net income may be calculated differently, and therefore the Company’s adjusted net income may not be comparable to similarly titled measures of other companies. Adjusted net income is not a measure of financial performance under U.S. generally accepted accounting principles (GAAP), and should not be considered in isolation or as an alternative to net income, cash flows from operating activities and other measures determined in accordance with GAAP. Items excluded from adjusted net income are significant and necessary components to the operations of the Company’s business, and, therefore, adjusted net income should only be used as a supplemental measure of operating performance.

Conference Call

The Company will hold a conference call at 8:00 a.m. ET on Monday, November 26, 2012 to discuss the third quarter 2012 financial results. Listeners may access the call by dialing:

United States toll free:		1-855-500-8701
China toll free:		400-1200654
Hong Kong toll free:		800-903737
United Kingdom toll free:		0800-0159724
International:		65-6723-9385
Conference ID:		64309501

A live webcast and replay of the earnings call will also be available through the Company’s website www.nkbp.com.

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (~~NASDAQ~~Nasdaq: NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in China. Nuokang’s principal products include Baquting®, China’s leading hemocoagulase product by market share, Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant product that addresses diabetic neuropathy. The Company’s product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.

~~Safe~~Forward-~~Harbor~~Looking ~~Statement~~Statements

This press release contains ~~statements of a~~ forward-looking ~~nature. These~~ statements, ~~including the management quotations and the statements~~ relating to ~~the~~ ~~Company’s new product development, are made under~~ the ~~“safe~~potential ~~harbor”~~acquisition ~~provisions~~ of the ~~Private~~Company ~~Securities~~by ~~Litigation~~an ~~Reform~~affiliate ~~Act~~ of ~~1995,~~Mr. Baizhong ~~including certain plans~~Xue, ~~expectations,~~the ~~goals,~~Chairman and ~~projections,~~Chief ~~which~~Executive ~~are~~Officer ~~subject~~of ~~to numerous~~the ~~assumptions, risks, and uncertainties~~Company. These are “forward-looking” statements ~~may~~within ~~include,~~the ~~but~~meaning ~~are~~of ~~not~~Section 27A ~~limited~~of ~~to,~~the ~~statements~~Securities ~~containing~~Act ~~words~~of ~~such~~1933, as ~~“may~~amended,” ~~“could,”~~and ~~“would,”~~Section 21E ~~“plan,”~~of ~~“anticipate,” “believe,”~~the ~~“estimate,”~~Securities ~~“predict,”~~Exchange ~~“potential,”~~Act ~~“expects~~of 1934,” ~~“intends”~~as ~~and “future” or similar expressions. Among other things~~amended, ~~the~~and ~~statements~~as ~~relating~~defined toin the ~~Company’s~~U.S. ~~expected~~Private ~~progress~~Securities onLitigation ~~the~~Reform ~~product~~Act ~~portfolio~~of ~~and~~1995. ~~future~~The ~~financial~~actual results ~~may~~of ~~contain~~the ~~forward-looking~~transaction ~~statements.~~could ~~These~~vary ~~forward-looking~~materially ~~statements~~as ~~speak~~a ~~only~~result as of ~~the~~a ~~date~~number of ~~this~~factors, ~~press~~including: ~~release~~uncertainties ~~and~~as ~~are subject~~ to ~~change~~how atthe ~~any time. These forward-looking statements are based upon management~~Company’s ~~current~~shareholders ~~expectations~~will ~~and~~vote ~~are~~at ~~subject~~the toextraordinary ageneral meeting; ~~number~~the ofpossibility ~~risks,~~that ~~uncertainties~~competing ~~and~~offers ~~contingencies,~~will ~~many~~be ofmade; ~~which~~and ~~are beyond~~ the ~~Company’s~~possibility ~~control~~ that ~~may~~various ~~cause~~closing ~~actual~~conditions ~~results,~~for ~~levels~~the oftransaction ~~activity, performance~~may ornot ~~achievements~~be tosatisfied ~~differ materially from any future results, levels of activity, performance~~ or ~~achievements~~waived. ~~expressed~~These ~~or implied by such~~ forward-looking statements. ~~The~~reflect the Company’s ~~actual~~expectations ~~results~~as ~~could~~of ~~differ materially from those~~the ~~contained~~date ~~in the forward-looking statements due to a number~~ of ~~factors,~~this ~~including~~press ~~those~~release. ~~described~~The ~~under~~Company ~~the~~does ~~heading~~not ~~“Risk~~undertake ~~Factors”~~any inobligation ~~the~~to ~~Company’s~~update ~~filings~~any ~~with~~forward-looking ~~the U.S. Securities and Exchange Commission~~statement, ~~including~~except ~~its~~as ~~annual~~required ~~report on~~under ~~Form~~applicable ~~20-F~~law.

~~CONSOLIDATED~~CONTACT: ~~STATEMENTS OF INCOME~~

FOR THE QUARTERS ENDED SEPTEMBER 30, 2011 AND 2012

	3Q 2011			3Q 2012						Nine Months 2011			Nine Months 2012
	(RMB’000)			(RMB’000)			(US$’000)			(RMB’000)			(RMB’000)			(US$’000)
Net revenue		87,247			75,397			11,997			231,253			208,587			33,189
Cost of revenue		(11,716	)		(9,019	)		(1,435	)		(28,602	)		(25,857	)		(4,114	)
Gross profit		75,531			66,378			10,562			202,651			182,730			29,075
Operating expenses
Research and development costs		(4,605	)		(4,136	)		(658	)		(12,102	)		(11,537	)		(1,836	)
Selling, marketing and distribution expenses		(41,620	)		(37,628	)		(5,987	)		(99,407	)		(105,219	)		(16,742	)
General and administrative expenses		(12,787	)		(19,514	)		(3,105	)		(35,657	)		(46,918	)		(7,465	)
Total operating expenses		(59,012	)		(61,278	)		(9,750	)		(147,166	)		(163,674	)		(26,043	)
Operating profit		16,519			5,100			812			55,485			19,056			3,032
Interest income		606			1,184			188			1,218			2,789			444
Interest expense		(831	)		(236	)		(38	)		(2,970	)		(710	)		(113	)
Foreign exchange (losses) gain		(1,579	)		100			16			(4,475	)		362			58
Other loss, net		(78	)		(28	)		(4	)		(175	)		(64	)		(10	)
Income before income tax expense		14,637			6,120			974			49,083			21,433			3,411
Income tax expense		(7,069	)		(3,605	)		(574	)		(16,472	)		(7,727	)		(1,229	)
Net income		7,568			2,515			400			32,611			13,706			2,182
Net (income) loss attributable to non-controlling interest		45			(2	)		—			105			(3	)		—
Net income attributed to ordinary shares		7,613			2,513			400			32,716			13,703			2,182
Net income per share
Basic		0.05			0.02			—			0.21			0.09			0.01
Diluted		0.05			0.02			—			0.21			0.09			0.01
Shares used in net income pershare computation
Basic		156,359,522			153,681,734			153,681,734			156,350,951			153,560,668			153,560,668
Diluted		157,631,522			154,390,734			154,390,734			157,231,116			154,246,544			154,246,544
Net income per ADS
Basic		0.39			0.13			0.02			1.67			0.71			0.11
Diluted		0.39			0.13			0.02			1.66			0.71			0.11
Shares used in net income per ADS computation
Basic		19,544,940			19,210,217			19,210,217			19,543,869			19,195,084			19,195,084
Diluted		19,703,940			19,298,842			19,298,842			19,653,890			19,280,818			19,280,818

CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2011 and SEPTEMBER 30, 2012

	December 31		September 30,
	2011		2012
	(RMB’000)		(RMB’000)		(US$’000)
ASSETS
Current assets:
Cash and cash equivalents		179,385		120,212		19,240
Restricted cash		5,410		—		—
Short-term investments		—		65,690		10,513
Accounts receivable (net of allowance for doubtful accounts of RMB393,860 and RMB393,860 (US$63,034) as of December 31, 2011 and September 30, 2012, respectively)		60,767		52,776		8,446
Bills receivable		109,256		99,013		15,846
Inventories		15,846		20,157		3,226
Prepayments		18,020		22,003		3,521
Other receivables		7,203		5,229		837
Prepaid income tax		8,179		14,838		2,375
Deferred tax assets		1,040		446		71
Total current assets		405,106		400,364		64,075
Non-current assets:
Property, plant and equipment, net		214,171		230,478		36,887
Land use rights, net		35,121		34,611		5,539
Intangible assets, net		21,212		19,429		3,109
Other Investments		3,414		3,414		546
Prepayments		15,884		31,640		5,064
Deferred tax assets		7,406		7,326		1,172
Total non-current assets		297,208		326,898		52,317
TOTAL ASSETS		702,314		727,262		116,392
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term bank loans		7,000		7,000		1,120
Accounts payable		1,501		3,031		485
Accrued expenses and other payables		34,863		38,799		6,209
Income tax payable		3,312		2,968		475
Unrecognized tax benefits		2,656		5,763		922
Total current liabilities		49,332		57,561		9,211
Non-current liabilities:
Deferred tax liabilities		2,036		2,336		374
Deferred government grants		23,185		26,697		4,273
Long-term payable		12,934		13,494		2,160
Total non-current liabilities		38,155		42,527		6,807
Commitments and contingencies		—		—		—
Shareholders’ equity:
Ordinary shares (par value US$0.0005 per share, 474,200,000 shares authorized and 157,906,470 shares issued and outstanding as of December 31, 2011; 474,200,000 shares authorized and 157,330,734 shares issued and outstanding as of September 30, 2012)		581		580		93
Additional paid-in capital		469,107		469,297		75,107
Retained earnings		143,180		155,335		24,860
Total shareholders’ equity		612,868		625,212		100,060
Non-controlling interests		1,959		1,962		314
TOTAL EQUITY		614,827		627,174		100,374
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		702,314		727,262		116,392

NKBP

Non GAAP Net Income

	Nine Months 2011		Nine Months 2012						3Q 2011		3Q 2012
	(RMB’000)		(RMB’000)			(USD$’000)			(RMB’000)		(RMB’000)			(USD$’000)
GAAP Net Income		32,716		13,703			2,180			7,613		2,513			400
Adjusting
Foreign Exchang Loss/(Gain)		4,475		(362	)		(58	)		1,579		(100	)		(16	)
ESOP		5,972		191			30			3,868		0			0
ASC 740 adjustment		0		3,107			494			0		1,607			256
Privatization expense		0		10,979			1,747			0		7,584			1,207
Non GAAP Net Income		43,163		27,618			4,394			13,060		11,604			1,846

Contact Information

China Nuokang Bio-Pharmaceutical Inc.

Mr. Steven Duan

Vice President of Investor Relations

Email: dsz@nkbp.com

ICR, Inc.

Mr. Rob Koepp

Tel: (+86) 10-6583-7516 or (646) 405-5180

Email: robert.koepp@icrinc.com

Filing Compare · China Nuokang Bio-Pharmaceutical Inc.